By Fineline Cube 
Zennova Pharmaceuticals Group and Rapafusyn Pharmaceuticals on Aug. 28, 2025 announced a strategic collaboration to jointly develop Rapafusyn’s RapaGlue molecular‑glue candidate, RAP‑8020, and other pipeline molecules. Zennova will leverage its proprietary BioCarier technology platform to optimize drug‑delivery systems for Rapafusyn’s candidates.
Strategic Partnership Overview
- Joint Development: Focus on RAP‑8020, a next‑generation molecular glue drug.
- Technology Leveraged: BioCarier, Zennova’s core platform for targeted delivery and controlled release.
- Scope: Immunology‑oncology targets, pain therapeutics, and kidney disease.
Target Portfolio
| Therapeutic Domain | Specific Targets | Clinical Rationale |
|---|---|---|
| Immunology | TNFαR1 pathway | Reduces inflammation in autoimmune disorders with high unmet need. |
| STAT6 transcription factor | Modulates allergic and atopic responses. | |
| Oncology | Myc‑driven tumors | Inhibits oncogenic transcription factor overexpressed in many cancers. |
| Cancer‑cell ferroptosis | Induces iron‑dependent cell death in resistant tumor cells. |
Future Expansion Plans
- Pain (Non‑Opioid Analgesics) – Explores FKBP12‑target protein regulation to deliver novel, opioid‑free pain relief.
- Kidney Disease – Applies BioCarier‑mediated delivery to modulate renal cellular pathways implicated in chronic kidney disease.
Commercial Outlook
- First‑to‑Market Advantage: RapaGlue’s unique mechanism positions it ahead of conventional biologics.
- Regulatory Pathway: Early engagement with regulatory bodies in China and the U.S. to streamline approval.
- Pipeline Synergy: Shared expertise accelerates candidate progression from pre‑clinical to clinical stages.-Fineline Info & Tech